Principles and Innovations in Peritoneal Surface Malignancy Treatment.

Area of Science:

• Oncology
• Surgical Oncology
• Chemotherapy

Background:

• Cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC) is a complex treatment modality for peritoneal malignancies.
• The rationale for CRS/HIPEC is based on principles of surgical oncology and regional chemotherapy delivery.
• Significant controversies and ongoing debates surround the efficacy and application of CRS/HIPEC.

Purpose of the Study:

• To review the scientific principles supporting the use of CRS/HIPEC.
• To discuss recent innovations in CRS/HIPEC techniques and applications.
• To explore the current controversies and limitations in the evidence base for CRS/HIPEC.

Main Methods:

• Literature review of scientific principles, innovations, and controversies related to CRS/HIPEC.
• Analysis of existing data and clinical evidence regarding CRS/HIPEC outcomes.
• Discussion of the impact of limited high-level evidence on treatment understanding.

Main Results:

• The scientific rationale for CRS/HIPEC involves combining maximal tumor debulking with regional hyperthermic chemotherapy.
• Recent innovations focus on improving drug delivery, patient selection, and surgical techniques.
• Ongoing controversies include patient selection criteria, optimal chemotherapy agents, and the definition of complete cytoreduction.

Conclusions:

• CRS/HIPEC is a technically demanding procedure with a specific scientific basis for treating peritoneal surface malignancies.
• Further research, particularly level 1 data, is crucial to definitively establish the role and benefit of CRS/HIPEC.
• Understanding the limitations of current evidence is essential for appropriate patient management and future trial design.